webinar register page

Webinar banner
InflaRx R&D Event
Virtual R&D Event - Vilobelimab in Hidradenitis Suppurativa

InflaRx will host a virtual R&D event on Thursday, February 3rd, beginning at 8:30 AM EST/2:30 PM CET.

The event will provide insight on the development of vilobelimab in Hidradenitis Suppurativa, including details on the study design and novel endpoint for the Phase III trial in this indication.

After registration, you will receive a dedicated link and dial-in details to easily and quickly access the event. Please note: Questions can only be asked via online participation and with full name registration.
Webinar logo
* Required information
This webinar contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our completed, planned and ongoing clinical trials of vilobelimab in hidradenitis suppurativa and the safety and efficacy results of those trials; the impact of the COVID-19 pandemic on the Company; the timing and our ability to commence and conduct clinical trials; potential results from current or potential future collaborations; our ability to make regulatory filings, obtain positive guidance from regulators, and obtain and maintain regulatory approvals for our product candidates, including based on the modified HiSCR as the primary endpoint for the Company’s Phase III trial of vilobelimab in HS; our intellectual property position; our ability to develop commercial functions; expectations regarding clinical trial data; our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies; the industry in which we operate; the trends that may affect the industry or us and the risks, uncertainties and other factors described under the heading “Risk Factors” in InflaRx’s periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this webinar and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.